Cancel
Ok
Etrasimod
Etrasimod
A drug candidate for the treatment of immune-mediated and inflammatory diseases. Etrasimod is an investigational, once-daily, oral, selective S1P receptor modulator designed to partially and reversibly reduce lymphocyte levels at sites of inflammation, while maintaining components of immune function.CLINICAL TRIALS
-
RISE UP AGAINST ULCERATIVE COLITIS (UC)
ClinicalTrials.gov: NCT03945188, NCT03996369, NCT03950232 -
ADDRESSING THE ROOT OF CROHN’S DISEASE (CD)
ClinicalTrials.gov: NCT04173273 Patient Trial Site -
BRINGING THE FIGHT TO UC
ClinicalTrials.gov: NCT04607837 -
Navigating a path forward in EoE
ClinicalTrials.gov: NCT04682639 Patient Trial Site
Clinical Trials
Etrasimod is an investigational drug and is not currently approved for use by any health authority.
ULCERATIVE COLITIS
CROHN’S DISEASE
EOSINOPHILIC ESOPHAGITIS
ATOPIC DERMATITIS
ALOPECIA AREATA